1800-272-662
Shopping Cart 0
countryflagAU
Login

Bioxyne Ltd

Consumer Defensive AU BXN

0.054AUD
-0.001(1.82%)

Last update at 2026-03-13T05:10:00Z

Day Range

0.050.06
LowHigh

52 Week Range

0.020.06
LowHigh

Fundamentals

  • Previous Close 0.06
  • Market Cap120.96M
  • Volume1238919
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA10.20M
  • Revenue TTM47.95M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 19.69M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax 4.90M -13.28529M -1.96444M -0.23651M -0.42573M
Minority interest - 0.18M - - 0.05M
Net income 4.90M -13.32505M -1.96444M -0.23651M -0.42573M
Selling general administrative 2.09M 2.57M 2.59M 0.88M 0.83M
Selling and marketing expenses 0.41M 0.41M 0.19M 0.02M 0.04M
Gross profit 10.45M 3.40M 1.90M 1.29M 1.08M
Reconciled depreciation - - 0.09M 0.05M 0.05M
Ebit 5.10M -13.28528M -2.04243M -0.15332M -0.26962M
Ebitda 5.34M -13.02517M -1.95584M -0.10327M -0.21972M
Depreciation and amortization 0.24M 0.26M 0.09M 0.05M 0.05M
Non operating income net other - - - - -
Operating income 5.56M -1.65857M -1.83573M -0.45306M -0.37412M
Other operating expenses 24.86M 10.98M 7.27M 0.96M 2.72M
Interest expense - 0.04M 0.00058M 0.00058M 0.00168M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.02M 0.02M 0.00257M 0.02M 0.02M
Net interest income - 0.02M 0.00257M 0.01M 0.02M
Extraordinary items 0.00000M -0.52607M - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.84005M -0.31064M 0.00715M 0.04M 0.06M
Total revenue 30.42M 9.33M 5.16M 2.42M 2.11M
Total operating expenses 4.89M 3.36M 4.04M 1.50M 1.43M
Cost of revenue 19.98M 5.93M 3.26M 1.13M 1.03M
Total other income expense net -0.65947M -11.62672M 0.09M -0.04376M -0.09470M
Discontinued operations - - - - -
Net income from continuing ops - -12.97465M -1.96444M -0.23651M -0.42573M
Net income applicable to common shares 4.90M -13.32505M -1.96444M -0.23651M -0.49573M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 20.90M 6.70M 17.69M 2.92M 2.75M
Intangible assets 0.39M - 0.03M 0.03M 0.03M
Earning assets - - - - -
Other current assets 3.03M 0.76M 0.07M 0.07M 0.05M
Total liab 9.53M 3.40M 2.69M 0.98M 0.74M
Total stockholder equity 11.68M 3.61M 15.14M 1.89M 1.95M
Deferred long term liab - - - - -
Other current liab 3.93M 1.49M 1.48M 0.89M 0.57M
Common stock 21.48M 19.00M 17.55M 62.18M 62.18M
Capital stock - - 17.55M 62.18M 62.18M
Retained earnings -10.70257M -15.59547M -2.48375M -60.47733M -60.17083M
Other liab - - - -0.00472M -
Good will - - 11.57M 11.57M -
Other assets - 0.00000M - - -
Cash 7.67M 1.03M 3.85M 2.17M 1.60M
Cash and equivalents - - - - -
Total current liabilities 8.45M 2.91M 2.69M 0.98M 0.74M
Current deferred revenue - 0.04M - - -0.04746M
Net debt -6.13407M -0.35427M -3.84597M -2.16801M -1.55475M
Short term debt 0.46M 0.18M 0.00000M 0.00000M 0.05M
Short long term debt - - - - -
Short long term debt total 1.53M 0.67M - - 0.05M
Other stockholder equity - - -15.06400M 0.19M -1.93671M
Property plant equipment - - 0.09M 0.07M 0.09M
Total current assets 17.14M 5.59M 6.04M 2.82M 2.58M
Long term investments - - - - -
Net tangible assets - - 3.57M 1.86M 1.81M
Short term investments - - - - -
Net receivables 2.35M 1.66M 0.90M 0.02M 0.34M
Long term debt - - - - -
Inventory 4.09M 2.14M 0.99M 0.31M 0.44M
Accounts payable 4.06M 1.19M 1.21M 0.10M 0.18M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.91M 0.20M 0.07M 0.19M -0.05575M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.29M -11.65303M - -0.16816M
Deferred long term asset charges - - - - -
Non current assets total 3.76M 1.11M 11.65M 0.10M 0.17M
Capital lease obligations - - - - -
Long term debt total - - 0.00000M 0.00000M 0.00000M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - -0.49266M 3.56M -0.00579M -
Change to liabilities - - 1.81M 0.24M 0.02M
Total cashflows from investing activities -2.41443M -0.49266M 3.56M -0.00579M -0.00579M
Net borrowings - - 0.37M 0.49M -0.04678M
Total cash from financing activities 2.76M 1.21M 1.35M -0.04678M -0.04678M
Change to operating activities - - - - -
Net income 4.90M -12.79898M -1.93997M -0.49402M -0.49573M
Change in cash 6.64M -2.81798M 3.78M 0.57M -0.14568M
Begin period cash flow 1.03M 3.85M 0.07M 1.60M 1.75M
End period cash flow 7.67M 1.03M 3.85M 2.17M 1.60M
Total cash from operating activities 6.28M -3.55995M -0.84128M -0.50681M 0.05M
Issuance of capital stock - 1.35M 0.58M - -
Depreciation 0.78M 0.26M 0.11M 0.03M 0.07M
Other cashflows from investing activities - -0.31418M 3.62M 0.09M -
Dividends paid - - - - -
Change to inventory -1.94764M -1.14712M -0.91926M -0.07555M 0.40M
Change to account receivables -2.97131M -1.21586M -0.59549M -0.26558M 0.02M
Sale purchase of stock 2.45M 1.35M 0.58M 0.00000M -
Other cashflows from financing activities 0.20M -0.13994M 0.77M -0.04678M -0.04678M
Change to netincome - - 0.70M 0.13M 0.03M
Capital expenditures 2.41M 0.49M 0.06M 0.00579M 0.03M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -4.91895M -2.36298M -1.51475M -0.34113M 0.41M
Stock based compensation 0.48M 0.14M 0.70M 0.10M -
Other non cash items 5.04M 11.34M 0.99M -0.04351M 0.07M
Free cash flow 3.86M -4.05261M -0.89992M -0.51260M 0.02M

Peer Comparison

Sector: Consumer Defensive Industry: Packaged Foods

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BXN
Bioxyne Ltd		 -0.001 1.82% 0.05 - 19.68 2.52 6.11 2.56 13.72
A2M
The a2 Milk Company Ltd		 0.10 1.05% 9.58 36.46 27.47 3.34 6.03 3.74 21.65
BGA
Bega Cheese Ltd		 0.06 1.04% 5.82 192.00 21.74 0.48 1.79 0.61 57.49
CBO
Cobram Estate Olives Ltd		 0.10 3.38% 3.06 29.60 - 6.05 2.77 6.91 14.78
RIC
Ridley Corporation Ltd		 0.10 3.75% 2.77 13.85 13.42 0.62 1.85 0.88 14.90

Reports Covered

Stock Research & News

View All

Profile

Bioxyne Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan. It operates through Pharmaceutical Manufacture and Wholesale Supply of Novel Medicines, Cannabis, Psilocybin, and MDMA; Manufacture and Distribution (Wholesale, Online, and Retail) of Consumer Health and Novel Food Products; and Wholesale of Patented Probiotics segments. The company offers active pharmaceutical ingredients and starting materials; plant-based food products, such as non-controlled cannabis extracts and cannabidiol; food grade mushroom extracts/psilocybin; medicinal and prescription cannabis products, including pastilles, vape, oral mucosal oils, flower, and suppositories; SL-NAD+ wafers; MDMA; white label manufactured wellness products; health and wellness supplements; and nootropic and skincare products. It also provides Lactobacillus fermentum VRI-003 PCC, a probiotic formulation for gastrointestinal health and immunity; Progastrim for gut and immune health; and proTract for atopic dermatitis. In addition, the company is involved in the contract manufacturing of final dose form products, including capsules, tablets, inhalables, oral solutions, and herbal preparations; import, export, manufacture, and supply of controlled drugs and medicinal products; research and development of formulations, products, and processes related to health, wellness, and medicine; and provision of telemedicine services. Further, it operates CanXChange, a machine-learning powered B2B wholesale and custody technology platform. The company offers its products to cultivators, manufacturers, pharmacies, clinics, and patients under the Breathe Life Science, Dr Watson, Mirai Solution, and Apothecary CBD brands. It sells its products through wholesale, retail, and online. Bioxyne Limited is headquartered in Sydney, Australia.

Bioxyne Ltd

50 Clarence Street, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Mr. Nam Hoat Chua B.A., BA MD, CEO & Director NA
Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), C.A., CA, MAICD CFO, Company Sec. & Exec. Director 1954
Ms. Rachel Qian Financial Controller & Assistant Company Sec. NA
Mr. Samuel Watson CEO, MD & Executive Director NA
Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICD CFO & Company Secretary 1953
Mr. Jason Hine COO & Executive Director NA
Ms. Rachel Qian Financial Controller & Assistant Company Secretary NA
Mr. Samuel Watson CEO, MD & Executive Director NA
Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICD CFO & Company Secretary 1953
Mr. Jason Hine COO & Executive Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.